Clinical trials: SGLT2 Inhibitor
Prediabetes, Impaired Fasting Glucose
Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes
Prediabetes is a term that refers to alterations in glucose homeostasis, including impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or both, involving a higher risk of progression type 2 diabetes mellitus (T2DM).
- Conditions
- Prediabetes, Impaired Fasting Glucose, Impaired Glucose Tolerance
- Trial name
- NCT02700334
- Testing
- Dapagliflozin
- Where
- Mexico
- Volunteers
- 24 people
- Sponsor
- University of Guadalajara
Type 2 Diabetes
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
The main purpose of this study is to determine the safety and efficacy of orforglipron. Participants will have Type 2 Diabetes (T2D) and have inadequate glycemic control with insulin glargine with or without metformin and/or…
- Trial name
- ACHIEVE-5 (NCT06109311)
- Testing
- Orforglipron
- Where
- 70 sites in United States, Brazil and 4 more
- Volunteers
- 546 people
- Sponsor
- Eli Lilly and Company
Transthyretin Amyloid Cardiomyopathy
SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy
This is a single center, single arm, prospective, 12 week open label pilot trial of the sodium-glucose cotransporter 2 inhibitor (SGLT2i), empagliflozin 10 mg oral daily, in patients with transthyretin amyloid cardiomyopathy…
- Trial name
- NCT05233163
- Testing
- Empagliflozin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Columbia University
Chronic Kidney Diseases, Proteinuria
Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria
This study tests the hypothesis that dapagliflozin lowers proteinuria in patients with non-diabetic chronic kidney disease.
- Trial name
- DIAMOND (NCT03190694)
- Testing
- Dapagliflozin 10mg
- Where
- 7 sites in Canada, Malaysia and 1 more
- Volunteers
- 53 people
- Sponsor
- Hiddo Lambers Heerspink
Heart Failure, Diastolic, Diabetes Mellitus, Type 2
Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure
This clinical trial will determine if subjects with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (DM2) receiving sodium-glucose cotransporter 2 (SGLTi2) inhibitor therapy (ertugliflozin)…
- Trial name
- EMMED-HF (NCT04071626)
- Testing
- Ertugliflozin 5 mg
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University Hospitals Cleveland Medical Center
Heart Failure
Informational Nudge to Improve Heart Failure Prescribing
This study addresses a critical gap of care for Veterans with heart failure (HF). Only 1/3 or fewer eligible Veterans are receiving recommended SGLT2 and MRA therapies that save lives and prevents HF hospitalizations.
- Trial name
- Nudge (NCT05986695)
- Testing
- Alert, Peer comparison report
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Diabetes, Diabetes Mellitus, Type 2
LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.
The trial is conducted in Asia, Europe, North America and South America. The aim of the study is to compare the effect of liraglutide 1.8 mg/day versus placebo as add-on to an SGLT2 inhibitor with or without metformin on…
- Trial name
- NCT02964247
- Testing
- liraglutide
- Where
- 82 sites in United States, Brazil and 5 more
- Volunteers
- 303 people
- Sponsor
- Novo Nordisk A/S